| Name | Fenbufen |
| Description | Fenbufen (Lederfen) is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation. |
| In vivo | Fenbufen and its metabolites could be involved in mitochondrial toxicity through inhibition of ATP synthesis[1]. Fenbufen inhibited prostaglandin release by 80% and reduced rates of protein synthesis in normal muscle and in muscle undergoing hypertrophy in response to tenotomy of a synergist[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 47 mg/mL (184.84 mM), Sonication is recommended.
DMSO : 47 mg/mL (184.84 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | tendinitis | osteoarthritis | Inhibitor | inhibit | Fenbufen | Cyclooxygenase | COX | CL82204 | CL 82204 | Caspase | ATP systhesis | antirheumatic | antipyretic | anti-inflammatory | ankylosing spondylitis | analgetic |
| Inhibitors Related | Bismuth Subsalicylate | Sodium oleate | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Salicylic acid | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | Apoptosis Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library |
United States
